CymaBay Therapeutics, Inc. (NASDAQ: CBAY) had its price target raised by analysts at Raymond James from $14.00 to $17.00. They now have a "strong-buy" rating on the stock.
CymaBay Therapeutics Inc. (CBAY)
Last cymabay therapeutics inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cymabay.com
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
CBAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CBAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CBAY alerts
High impacting CymaBay Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
CBAY
News
- Gilead posts quarterly loss, revenue rises 5% [Reuters]Reuters
- Gilead posts quarterly loss, revenue rises 5% [Yahoo! Finance]Yahoo! Finance
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain [Yahoo! Finance]Yahoo! Finance
CBAY
Earnings
- 11/7/23 - Miss
CBAY
Sec Filings
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- 3/22/24 - Form 4
- CBAY's page on the SEC website